Flow cytometric diagnosis of myelodysplasia and myeloproliferative disorders

Journal of Biological Regulators and Homeostatic Agents

Volumn 18, Issue 2, 2004, Pages 141-145

  Wood, Brent L ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

Diagnosis; Flow cytometry; Immunophenotyping; Myelodysplasia; Myeloproliferative

Indexed keywords

CD11B ANTIGEN; CD16 ANTIGEN; CD2 ANTIGEN; CD34 ANTIGEN; CD5 ANTIGEN; CD7 ANTIGEN; DIPEPTIDYL PEPTIDASE IV; HLA DR ANTIGEN; STEM CELL FACTOR RECEPTOR;

ANTIGEN EXPRESSION; ARTICLE; BONE MARROW CELL; CANCER STAGING; CHROMOSOME STRUCTURE; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ERYTHROID CELL; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; MEDICAL LITERATURE; MEGAKARYOCYTE; MYELODYSPLASIA; MYELOPROLIFERATIVE DISORDER; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION;

EID: 5744230318     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Loken MR, Wells DA. Normal antigen expression in hematopoiesis: Basis for interpreting leukemia phenotypes. In: Stewart C, Nicholson JKA, eds by Carleton. Immunophenotyping. New York: Wiley-Liss 2000; 133-60.
2. Terstappen LW, Loken MR. Myeloid cell differentiation in normal bone marrow and acute myeloid leukemia assessed by multi-dimensional flow cytometry. Anal Cell Pathol 1990; 2: 229-40.
3. Terstappen LW, Safford M, Loken MR. Flow cytometric analysis of human bone marrow. III. Neutrophil maturation. Leukemia 1990b; 4: 657-63.
4. Wood BL. Multicolor immunophenotyping. Human immune system hematopoiesis. Methods in Cell Biology 2004; (in press).
5. Elghetany MT. Surface marker abnormalities in myelodysplastic syndromes. Haematologica 1998; 83: 1104-15.
6. Bianco T, Farmer BJ, Sage RE, Dobrovic A. Loss of red cell A, B, and H antigens is frequent in myeloid malignancies. Blood. 2001; 97: 3633-9.
7. Izumi M, Takeshita A, Shinjo K, et al. Decreased amount of mpl and reduced expression of glycoprotein IIb/IIIa and glycoprotein Ib on platelets from patients with refractory anemia: analysis by a non-isotopic quantitative ligand binding assay and immunofluorescence. Eur J Haematol. 2001; 66: 245-52.
8. Bowen KL, Davis BH. Abnormal patterns of expression of CD16 (FcR-III) and CD11 b (CRIII) in the bone marrow of patients with myelodysplastic syndrome. Lab Hematol 1997; 3: 292-8.
9. Hansen I, Meyer K, Hokland P. Flow cytometric identification of myeloid disorders by asynchronous expression of the CD14 and CD66 antigens. Eur J Haematol 1998; 61: 339-46.
10. Chang CC, Cleveland RP. Decreased CD10-positive mature granulocytes in bone marrow from patients with myelodysplastic syndrome. Arch Pathol Lab Med 2000; 124: 1152-6.
11. Ohsaka A, Saionji K, Igari J, Watanabe N, Iwabuchi K, Nagaoka I. Altered surface expression of effector cell molecules on neutrophils in myelodysplastic syndromes. Br J Haematol 1997; 98: 108-13.
12. Otawa M, Kawanishi Y, Iwase O, Shoji N, Miyazawa K, Ohyashiki K. Comparative multi-color flow cytometric analysis of cell surface antigens in bone marrow hematopoietic progenitors between refractory anemia and aplastic anemia. Leuk Res 2000; 24: 359-66.
13. Mann KP, DeCastro CM, Liu J, et al. Neural cell adhesion molecule (CD56)-positive acute myelogenous leukemia and myelodysplastic and myeloproliferative syndromes. Am J Clin Pathol 1997; 107: 653-60.
14. Schlesinger M, Silverman LR, Jiang JD, Yagi MJ, Holland JF, Bekesi JG. Analysis of myeloid and lymphoid markers on the surface and in the cytoplasm of mononuclear bone marrow cells in patients with myelodysplastic syndrome. J Clin Lab Immunol 1996; 48: 149-66.
15. Stetler-Stevenson M, Arthur DC, Jabbour N, et al. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 2001; 98: 979-87.
16. Ogata K, Nakamura K, Yokose N, et al. Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood 2002; 100: 3887-96.
17. Maynadie M, Picard F, Husson B, et al. Groupe d'Etude Immunologique des Leucemies (GEIL). Immunophenotypic clustering of myelodysplastic syndromes. Blood 2002; 100: 2349-56.
18. Del Canizo MC, Fernandez ME, Lopez A, et al. Immunophenotypic analysis of myelodysplastic syndromes. Haematologica 2003; 88: 402-7.
19. Wells DA, Benesch M, Loken MR, Vallejo C, Myerson D, Leisenring WM, Deeg HJ. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 2003; 102: 394-403.
20. Kussick SJ, Fromm J, Rossini A, et al. Four-color flow cytometry shows strong concordance with bone marrow morphology and cytogenetics in the workup of myelodysplasia. Am J Clin Pathol 2004; (submitted).
21. Kussick S, Wood BL. Using four-color flow cytometry to identify abnormal myeloid populations. Arch Pathol Lab Med 2003; 127: 1140-7.
22. Carulli G, Gianfaldoni ML, Azzara A, et al. FcRIII (CD16) expression on neutrophils from chronic myeloid leukemia. A flow cytometric study. Leuk Res 1992; 16: 1203-9.
23. Kant AM, Advani SH, Zingde SM. Heterogeneity in the expression of Fc gammaRIII in morphologically mature granulocytes from patients with chronic myeloid leukemia. Leuk Res 1997; 21: 225-34.
24. Kabutomori O, Iwatani Y, Koh T, et al. CD16 antigen density on neutrophils in chronic myeloproliferative disorders. Am J Clin Pathol 1997; 107: 661-4.
25. Kawaishi K, Kimura A, Katoh O, et al. Decreased L-selectin expression in CD34-positive cells from patients with chronic myelocytic leukemia. Br J Haematol 1996: 93: 367-74.
26. Lanza F, Bi S, Castoldi G, et al. Abnormal expression of N-CAM (CD56) adhesion molecule on myeloid and progenitor cells from chronic myeloid leukemia. Leukemia 1993; 7: 1570-5.
27. Mann KP, DeCastro CM, Liu J, et al. Neural cell adhesion molecule (CD56)-positive acute myelogenous leukemia and myelodysplastic and myeloproliferative syndromes. Am J Clin Pathol 1997; 107: 653-60.
28. Launder TM, Bray RA, Stempora L, et al. Lymphoid-associated antigen expression by acute myeloid leukemia. Am J Clin Path 1996; 106: 185-91.
29. Normann AP, Egeland T, Madshus IH, Heim S, Tjonnfjord GE. CD7 expression by CD34+ cells in CML patients, of prognostic significance? Eur J Haematol 2003; 71: 266-75.
30. Kosugi N, Tojo A, Shinzaki H, Nagamura-Inoue T, Asano S. The preferential expression of CD7 and CD34 in myeloid blast crisis in chronic myeloid leukemia. Blood 2000; 95: 2188-9.
31. Martin-Henao GA, Quiroga R, Sureda A, Garcia J. CD7 expression on CD34+ cells from chronic myeloid leukaemia in chronic phase. Am J Hematol 1999; 61: 178-86.
32. Silva M, Richard C, Benito A, et al. Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. N Engl J Med 1998; 338: 564-71.
33. Handa M, Watanabe K, Kawai Y, et al. Platelet unresponsiveness to collagen: involvement of glycoprotein Ia-IIa (alpha 2 beta 1 integrin) deficiency associated with a myeloproliferative disorder. Thromb Haemost 1995; 73: 521-8.
34. Jensen MK, de Nully-Brown P, Lund BV, et al. Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders. Br J Haematol 2000; 110: 116-24.
35. Griesshammer M, Beneke H, Nussbaumer B, et al. Increased platelet surface expression of P-selectin and thrombospondin as markers of platelet activation in essential thrombocythaemia. Thromb Res 1999; 96: 191-6.
36. Li J, Xia Y, Kuter DJ. The platelet thrombopoietin receptor number and function are markedly decreased in patients with essential thrombocythaemia. Br J Haematol 2000; 111: 943-53.
37. Hansen I, Meyer K, Hokland P. Flow cytometric identification of myeloid disorders by asynchronous expression of the CD14 and CD66 antigens. Eur J Haematol 1998; 61: 339-346.
38. Kussick SJ, Wood BL. Four-color flow cytometry identifies virtually all cytogenetically abnormal bone marrow samples in the workup of non-CML myeloproliferative disorders. Am J Clin Pathol 2003; 120: 854-65.